BioCentury | Nov 10, 2020
Product Development

Pfizer & Biogen: The good, the bAD and what’s next

COVID-19 vaccine data from Pfizer and BioNTech have set a high bar for what could be a rapid wave of readouts from other companies developing vaccines accelerated by surges in case counts. In the latest...
BioCentury | Nov 3, 2020
Politics, Policy & Law

ICER’s influence & election effects: a BioCentury podcast

In the latest BioCentury this Week podcast, BioCentury editors discuss ICER’s growing influence on conversations around drug pricing, implications for the biopharma industry following Tuesday’s election, and tough decisions ahead for FDA as the leading...
BioCentury | Oct 6, 2020
Politics, Policy & Law

Treating Trump & BMS’s $13B MyoKardia buy: a BioCentury podcast

In the latest BioCentury This Week podcast, BioCentury’s editors discuss access to Regeneron’s experimental COVID-19 therapy, fallout from last week’s House drug pricing hearings, Bristol Myers’ heart pumping $13 billion takeout of MyoKardia and the outlook...
BioCentury | Feb 28, 2020
Distillery Therapeutics

Boosting OSM and TIMP1 levels to treat demyelinating diseases

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis (MS) Promoting expression of OSM or its downstream mediator TIMP1 could treat demyelinating diseases such as MS. In cultures of oligodendrocyte precursor cells, which differentiate into the myelinating...
BioCentury | Jan 1, 2020
Company News

Fewer FDA approvals in 2019, but a basket of firsts

While the year held fewer approvals of new molecular entities than 2018, it was not short of major achievements. FDA greenlit several drugs with innovative modalities, against novel targets and for diseases that have long...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

BioCentury, like the biomedical innovation ecosystem it serves, is relentlessly focused on the future, but the turn of a decade is a good time to check in on the progress industry has made possible --...
BioCentury | Nov 14, 2017

Rules of engagement

An upcoming publication from the National Health Council on good practices for sponsor-patient interactions could help companies overcome fears that their outreach could be construed as promotional. Several executives told BioCentury that having guardrails established...
BioCentury | Oct 3, 2016

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
BioCentury | May 23, 2016
Politics, Policy & Law

Plan B for Part B?

PhRMA and BIO's "hell no" responses to CMS's plan to change the way Medicare Part B pays for drugs have set the stage for a confrontation that will test the industry's ability to fend off...
BioCentury | Apr 4, 2016

Ample opportunity

While some investors are sifting through formerly high-flying names for bargains, event-driven buysiders have a full plate of late-stage milestones in 2Q16. The quarter promises more than 30 Phase III data readouts and PDUFA dates....
Items per page:
1 - 10 of 105